Efficacy of Elbasvir/Grazoprevir Therapy in HCV Genotype-1 with or without HIV Infection: Role of HCV Core Antigen Monitoring and Improvement of Liver Stiffness and Steatosis

MLA

Natthaya Chuaypen, et al. “Efficacy of Elbasvir/Grazoprevir Therapy in HCV Genotype-1 with or without HIV Infection: Role of HCV Core Antigen Monitoring and Improvement of Liver Stiffness and Steatosis.” Antiviral Therapy, vol. 25, Aug. 2019, pp. 305–14. EBSCOhost, https://doi.org/10.3851/imp3370.

APA

Natthaya Chuaypen, Maneerat Chayanupatkul, Pisit Tangkijvanich, S. Chittmittraprap, Anchalee Avihingsanon, & Pornpitra Pratedrat. (2019). Efficacy of Elbasvir/Grazoprevir Therapy in HCV Genotype-1 with or without HIV Infection: Role of HCV Core Antigen Monitoring and Improvement of Liver Stiffness and Steatosis. Antiviral Therapy, 25, 305–314. https://doi.org/10.3851/imp3370

Chicago

Natthaya Chuaypen, Maneerat Chayanupatkul, Pisit Tangkijvanich, S. Chittmittraprap, Anchalee Avihingsanon, and Pornpitra Pratedrat. 2019. “Efficacy of Elbasvir/Grazoprevir Therapy in HCV Genotype-1 with or without HIV Infection: Role of HCV Core Antigen Monitoring and Improvement of Liver Stiffness and Steatosis.” Antiviral Therapy 25 (August): 305–14. doi:10.3851/imp3370.